Ultrasound-actuated ion homeostasis perturbator for oxidative damage-augmented Ca2+ interference therapy and combined immunotherapy
Source abstract
Abstract
Calcium ion therapy has shown promise for cancer treatment, but its efficacy is limited by the cellular calcium buffering mechanism. Herein, an ion homeostasis disruptor (PCCa) was synthesized using an in situ mineralization method. The surface of the porphyrin-metal-organic framework PCN was coated with calcium carbonate (CaCO 3 ), aimed at causing Ca 2+ overload and disrupting the self-defense mechanism during ion imbalance. Upon internalization into tumor cells, PCCa undergoes lysosomal acidification-induced CaCO 3 decomposition, leading to instantaneous Ca 2+ overload. Simultaneously, under ultrasonic irradiation, the meso-tetra-(4-carboxyphenyl)porphine (TCPP) within the ion homeostasis disruptor generates reactive oxygen species (ROS), which impairs cellular calcium buffering capacity and amplifies cell damage caused by calcium overload. In addition, PCCa could also induce immunogenic cell death, release tumor-associated antigens (TAA), and act as an adjuvant, thereby promoting dendritic cell maturation and enhancing the antitumor activity of CD8 + T cells. In mouse models, PCCa not only led to significant regression of subcutaneous mammary tumors but also demonstrated substantial anti-metastatic effects. In summary, the proposed ultrasound-actuated Ca 2+ interference strategy is promising to deactivate the ion homeostasis maintenance system, contributing to the attainment of splendid tumor treatment outcome with reliable biosafety, which may provide useful insights in cancer therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Ultrasound and Hyperthermia Applications · Luminescence and Fluorescent Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. Cancer statistics
2. Breast cancer: an up-to-date review and future perspectives10.1002/cac2.12358 ↗
3. Breast cancer10.1016/S0140-6736(16)31891-8 ↗
4. Therapeutic resistance to anti-oestrogen therapy in breast cancer10.1038/s41568-023-00604-3 ↗
5. The complex biology of the obesity-induced, metastasis-promoting tumor microenvironment in breast cancer10.3390/ijms23052480 ↗
6. Targeting the autophagy-miRNA axis in prostate cancer: toward novel diagnostic and therapeutic strategies10.1007/s00210-024-03153-0 ↗
7. Cancer stem cell metabolism: target for cancer therapy10.5483/BMBRep.2018.51.7.112 ↗
8. Targeting calcium signaling in cancer therapy10.1016/j.apsb.2016.11.001 ↗
9. Ca(2+) fluxes and cancer10.1016/j.molcel.2020.04.017 ↗
10. Circadian regulated control of myocardial ischemia-reperfusion injury10.1016/j.tcm.2022.09.003 ↗
11. Mitochondrial calcium: transport and modulation of cellular processes in homeostasis and cancer
12. Cancer-related increases and decreases in calcium signaling at the endoplasmic reticulum-mitochondria interface (MAMs), reviews of physiology
13. Ca(2+) signaling and cell death10.1016/j.ceca.2023.102759 ↗
14. Synergistic reinforcing of immunogenic cell death and transforming tumor-associated macrophages via a multifunctional cascade bioreactor for optimizing cancer immunotherapy10.1002/adma.202207593 ↗
15. Metalloimmunology: the metal ion-controlled immunity10.1016/bs.ai.2019.11.007 ↗
16. Mineralized porphyrin metal-organic framework for improved tumor elimination and combined immunotherapy10.1021/acsnano.3c02126 ↗
17. Disulfiram loaded calcium phosphate nanoparticles for enhanced cancer immunotherapy10.1016/j.biomaterials.2022.121880 ↗
18. Transformable nanosensitizer with tumor microenvironment-activated sonodynamic process and calcium release for enhanced cancer immunotherapy10.1002/anie.202102703 ↗
19. Al Omari · 2016 · vol. 41 · 31
20. Calcium carbonate carriers for combined chemo- and radionuclide therapy of metastatic lung cancer10.1016/j.jconrel.2022.02.021 ↗
21. Ion pathways in biomineralization: perspectives on uptake, transport, and deposition of calcium, carbonate, and phosphate10.1021/jacs.1c09174 ↗
22. A transporter that allows phosphate ions to control the polymorph of exoskeletal calcium carbonate biomineralization10.1016/j.actbio.2024.02.035 ↗
23. Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma10.1016/j.clim.2023.109772 ↗
24. Bioreducible exosomes encapsulating glycolysis inhibitors potentiate mitochondria-targeted sonodynamic cancer therapy via cancer-targeted drug release and cellular energy depletion10.1016/j.biomaterials.2023.122242 ↗
25. Sonodynamic-immunomodulatory nanostimulators activate pyroptosis and remodel tumor microenvironment for enhanced tumor immunotherapy10.7150/thno.79945 ↗
26. Current status of porous coordination networks (PCNs) derived porphyrin spacers for cancer therapy10.1080/17425247.2023.2260309 ↗
27. Monodispersed calcium carbonate nanoparticles modulate local pH and inhibit tumor growth in vivo10.1039/C5NR06162H ↗
28. Erythrocyte membrane-camouflaged PCN-224 nanocarriers integrated with platinum nanoparticles and glucose oxidase for enhanced tumor sonodynamic therapy and synergistic starvation therapy10.1021/acsami.1c05644 ↗
29. Intracellular fate and immune response of porphyrin-based nano-sized metal-organic frameworks
30. Photochemically-driven highly efficient intracellular delivery and light/hypoxia programmable triggered cancer photo-chemotherapy10.1186/s12951-023-01774-w ↗
31. Metal-organic framework PCN-224 combined cobalt oxide nanoparticles for hypoxia relief and synergistic photodynamic/chemodynamic therapy10.1002/chem.202400319 ↗
32. Defective homojunction porphyrin-based metal-organic frameworks for highly efficient sonodynamic therapy10.1002/smtd.202201248 ↗
33. Calcium carbonate-actuated ion homeostasis perturbator for oxidative damage-augmented Ca(2+)/Mg(2+) interference therapy10.1016/j.biomaterials.2023.122340 ↗
34. Endocytosis at the nanoscale10.1039/c2cs15309b ↗
35. Nano-modulators with the function of disrupting mitochondrial Ca(2+) homeostasis and photothermal conversion for synergistic breast cancer therapy10.1186/s12951-023-02220-7 ↗
36. Nanotechnology in cancer diagnosis and treatment10.3390/pharmaceutics15031025 ↗
37. Hydroxyapatite nanoparticles induced calcium overload-initiated cancer cell-specific apoptosis through inhibition of PMCA and activation of calpain10.1039/D3TB00542A ↗
38. Efficacy-shaping nanomedicine by loading calcium peroxide into tumor microenvironment-responsive nanoparticles for the antitumor therapy of prostate cancer10.7150/thno.43631 ↗
39. Naringin-generated ROS promotes mitochondria-mediated apoptosis in Candida albicans10.1002/iub.2476 ↗
40. Growth hormone activates PI3K/Akt signaling and inhibits ROS accumulation and apoptosis in granulosa cells of patients with polycystic ovary syndrome10.1186/s12958-020-00677-x ↗
41. PAMPs and DAMPs: signal 0s that spur autophagy and immunity10.1111/j.1600-065X.2012.01146.x ↗
42. An overview of high-mobility group box 1, a potent pro-inflammatory cytokine in asthma10.1515/jbcpp-2019-0363 ↗
43. P2Y2R-mediated inflammasome activation is involved in tumor progression in breast cancer cells and in radiotherapy-resistant breast cancer
44. Effects of calreticulin mutations on cell transformation and immunity10.1111/jcmm.17713 ↗
45. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy10.1038/ncomms13193 ↗
46. A designer scaffold with immune nanoconverters for reverting immunosuppression and enhancing immune checkpoint blockade therapy10.1002/adma.201903242 ↗